Cargando…

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review

Metastatic urothelial carcinoma (mUC) has a poor prognosis with a 5-year survival probability of 4.8%. The mainstay of first-line treatment is platinum-based chemotherapy. Second-line therapy involves immune checkpoint inhibitors or a fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Katherine Emilie Rhoades, Hitron, Emilie Elise, Russler, Greta A, Baumgarten, Deborah A, Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208383/ https://www.ncbi.nlm.nih.gov/pubmed/35756183 http://dx.doi.org/10.4103/JIPO.JIPO_22_19

Ejemplares similares

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature
por: Ravindranathan, Deepak, et al.
Publicado: (2018)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series
por: Ravindranathan, Deepak, et al.
Publicado: (2021)

A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
por: Rhoades Smith, Katherine Emilie, et al.
Publicado: (2019)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
por: Necchi, Andrea, et al.
Publicado: (2020)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
por: van der Heijden, Michiel S., et al.
Publicado: (2022)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
por: Matsumoto, Kinnosuke, et al.
Publicado: (2021)

Management of metastatic renal cell carcinoma: The complexity of choice
por: Brown, Jacqueline T., et al.
Publicado: (2019)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
por: Rezvani, Hamid, et al.
Publicado: (2022)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
por: Ellis-Caleo, Tim, et al.
Publicado: (2021)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
por: Kareff, Samuel A., et al.
Publicado: (2023)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer
por: Roviello, Giandomenico, et al.
Publicado: (2018)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2022)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
por: de Wit, Ronald, et al.
Publicado: (2022)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review
por: Fujii, Teruhiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v375b0gdeoje8gf4kj0r6ojbpn